Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nextleaf Solutions Ltd. (OILS.CN)
Vancouver, BC, CA
Nextleaf Solutions Ltd. operates as a cannabis extraction technology enterprise, pioneering and licensing advanced methods for the processing, refinement, and development of cannabinoid formulations throughout Canada. The company is actively involved in the extraction, distillation, and purification of CBD oils and THC ingredients, which it subsequently distributes and sells wholesale. Its operations further encompass comprehensive research and development for cannabis-infused products, including vaporizers, edible concentrates, and specialized extracts, in addition to providing expert extraction services. Nextleaf also dedicates efforts to the creation and market introduction of psychoactive compounds. Established in 2015, the firm is headquartered in Vancouver, Canada, and was previously known as Legion Metals Corp.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -9.09% | -9.09% | -9.09% | +11.11% | -9.09% | -16.67% | -16.67% | -78.72% | -87.01% | -87.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-9.7% Q1'26: -31.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+88.8% ★ Q1'26: -281.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.8% Q1'26: -7.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-1.0% Q1'26: -26.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-2.2% Q1'26: -59.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.0% Q1'26: +1.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.30× Q1'26: -0.17× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. |
Sep 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
690.7K
est: 35.80M (-98.1%)
|
3.38M
est: 119.40M (-97.2%)
|
4.41M
est: 35.80M (-87.7%)
|
8.18M
est: 119.40M (-93.1%)
|
12.48M
est: 119.40M (-89.5%)
|
11.26M
est: 35.80M (-68.5%)
|
35.80M
35.80M – 35.80M
+0.0% YoY
|
119.40M
119.40M – 119.40M
+233.5% YoY
|
| EBITDA |
-4.80M
est: -16.83M (+71.5%)
|
-3.79M
est: -56.14M (+93.2%)
|
-1.94M
est: -16.83M (+88.5%)
|
1.14M
est: -56.14M (+102.0%)
|
-624.4K
est: -30.96M (+98.0%)
|
611.7K
est: -9.28M (+106.6%)
|
-9.28M
-9.28M – -9.28M
+0.0% YoY
|
-30.96M
-30.96M – -30.96M
-233.5% YoY
|
| EBIT |
-5.91M
est: -19.44M (+69.6%)
|
-5.00M
est: -64.83M (+92.3%)
|
-2.86M
est: -19.44M (+85.3%)
|
366.8K
est: -64.83M (+100.6%)
|
-1.38M
est: -41.18M (+96.7%)
|
-107.8K
est: -12.35M (+99.1%)
|
-12.35M
-12.35M – -12.35M
+0.0% YoY
|
-41.18M
-41.18M – -41.18M
-233.5% YoY
|
| Net Income |
-5.95M
|
-5.39M
|
-3.49M
|
223.3K
|
-1.44M
|
-162.9K
|
—
— – —
|
—
— – —
|
| SGA |
4.82M
est: 67.48M (-92.9%)
|
3.68M
est: 225.05M (-98.4%)
|
3.36M
est: 67.48M (-95.0%)
|
1.64M
est: 225.05M (-99.3%)
|
4.85M
est: 62.63M (-92.3%)
|
2.05M
est: 18.78M (-89.1%)
|
18.78M
18.78M – 18.78M
+0.0% YoY
|
62.63M
62.63M – 62.63M
+233.5% YoY
|
| EPS |
-0.05
|
-0.04
|
-0.03
|
0.00
|
-0.01
|
0.00
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Emma Andrews | Chief Executive Officer, President & Director | 177.0K | female |
| Ryan Delmoral Ko | Co-Founder and Vice President of Innovation & Tech | 168.0K | male |
| Sam Kassem | Chief Financial Officer & Director | 90.0K | male |
| Charles Joudrey Ackerman | Co-Founder & Board Advisor | 63.0K | male |
| Catherine Marion | Director of Operations | — | female |
| Mary-Aaron | Director of Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OILS.CN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
